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Abstract Venous thromboembolism (VTE) is catego-
rized by the U.S. Surgeon General as a major public health
problem. VTE is relatively common and associated with
reduced survival and substantial health-care costs, and
recurs frequently. VTE is a complex (multifactorial) dis-
ease, involving interactions between acquired or inherited
predispositions to thrombosis and VTE risk factors,
including increasing patient age and obesity, hospitaliza-
tion for surgery or acute illness, nursing-home confine-
ment, active cancer, trauma or fracture, immobility or leg
paresis, superficial vein thrombosis, and, in women, preg-
nancy and puerperium, oral contraception, and hormone
therapy. Although independent VTE risk factors and pre-
dictors of VTE recurrence have been identified, and
effective primary and secondary prophylaxis is available,
the occurrence of VTE seems to be relatively constant, or
even increasing.
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Introduction
Thrombosis can affect virtually any venous circulation.
This chapter focuses on the epidemiology of venous
thromboembolism (VTE), including deep vein thrombosis
(DVT) of the leg or pelvis, and its complication, pulmonary
embolism (PE). Thrombosis affecting the superficial leg
(e.g. saphenous) veins and other venous circulations (e.g.
arm, cerebral, mesenteric, renal, hepatic, portal veins) is
beyond the scope of this chapter. VTE is a complex
(multifactorial) disease, involving interaction between
acquired or inherited predispositions to thrombosis (i.e.
thrombophilia) and environmental exposures (i.e. clinical
risk factors) [1–5]. Moreover, the type of VTE event (PE
vs. DVT) may also be partly heritable [6, 7]. Most studies
of VTE epidemiology addressed populations of predomi-
nantly European origin, and the data discussed in this
chapter mainly relate to these populations. Where avail-
able, data from populations originating from other conti-
nents are presented.
Methods
This chapter focuses on population-based studies and
addresses nine questions regarding the epidemiology of
VTE (Table 1). Questions were developed by consensus
from the authors. The literature addressing the above
questions was reviewed by searching electronic databases
(PubMed, Medline), including the references of all identi-
fied papers and the author’s personal libraries. Since this
review is informational only and does not address diag-
nosis, treatment or management of VTE, there are no
associated guidance statements. The post thrombotic syn-
drome and the epidemiology of inherited and acquired
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thrombophilia are reviewed in Chapters 9 and 10,
respectively.
Questions
(1) What is the incidence of VTE, PE with or without
(±) DVT and leg DVT alone, both overall, and by
age, sex and race, and by idiopathic versus sec-
ondary VTE?
The estimated average annual incidence rate of overall
VTE among persons of European ancestry ranges from 104
to 183 per 100,000 person-years [8–18]; overall VTE
incidence is similar to that of stroke [19, 20]. Overall VTE
incidence may be higher in African-Americans [21–23]
and lower in Asians [24], and Asian- [25, 26] and Native-
Americans [27], and may differ among African-Americans
by United States region [23]. Reported incidence rates for
PE ± DVT, and for leg DVT alone, range from 29 to 78,
and 45 to 117, per 100,000 person-years, respectively [10,
12, 14–18].
VTE is predominantly a disease of older age; VTE is
rare prior to late adolescence [8, 10–15, 18]. Incidence
rates increase markedly with age for both men and women
(Fig. 1) and for both DVT and PE (Fig. 2) [10, 14, 15]. The
overall age-adjusted incidence rate is higher for men (130
per 100,000) then women (110 per 100,000; male:female
sex ratio is 1.2:1) [10, 15]. Incidence rates are somewhat
higher in women during childbearing years, while inci-
dence rates after age 45 years are generally higher in men.
PE accounts for an increasing proportion of VTE with
increasing age for both sexes [10]. The percentage of
incident VTE events that are idiopathic ranges from 25 to
40 % [26, 28, 29]. In one study, 19 % of events among
Asian/Pacific Islanders were idiopathic [26].
(2) What are the trends in incidence over time of overall
VTE, leg DVT alone and PE ± DVT, and of idio-
pathic versus secondary VTE? How are these trends
Table 1 Guidance questions to be considered
(1) What is the incidence of VTE, PE with or without (±) DVT and leg DVT alone, both overall, and by age, sex and race, and by idiopathic
versus secondary VTE?
(2) What are the trends in incidence over time of overall VTE, leg DVT alone and PE ± DVT, and of idiopathic versus secondary VTE? How
are these trends affected by changes in diagnostic test utilization, imaging resolution and autopsy rates over time?
(3) What is the cumulative incidence of VTE recurrence, both overall and by leg DVT alone versus PE ± DVT?
(4) What baseline and time-dependent characteristics are independent predictors of VTE recurrence after adjustment for primary treatment
and secondary prophylaxis? Within the major predictors of VTE recurrence, can the individual patient be further stratified into high and low
risk? How well do available VTE recurrence risk-prediction scores operate in predicting recurrence?
(5) What are the attack rates (i.e. incident and recurrent VTE) of VTE, both overall and by hospitalization-related versus community-acquired
VTE? What is the total number of VTE events (incident and recurrent) per year in the USA?
(6) What are the VTE-attributable costs?
(7) What is the survival after VTE overall, and after leg DVT alone vs. PE ± DVT. What are the independent predictors of survival? What
are the trends in survival over time after PE ± DVT?
(8) What are the independent risk factors for VTE? How well do incident VTE risk prediction scores operate in predicting incident VTE for
the individual?
Fig. 1 Annual incidence of venous thromboembolism by age and sex
[10]
Fig. 2 Annual incidence of all venous thromboembolism, deep vein
thrombosis (DVT) alone, and pulmonary embolism with or without
deep vein thrombosis (PE ± DVT) by age [10]
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affected by changes in diagnostic test utilization,
imaging resolution and autopsy rates over time?
Data on trends in VTE incidence are limited; overall
VTE incidence rates as well as incidence rates for
PE ± DVT and DVT alone either remained relatively
constant or increased for the period, 1981-2000, with a
significant increase in the overall VTE incidence rate from
2001 to 2009, mostly due to an increasing incidence of
PE ± DVT (Fig. 3) [10, 14, 18, 30]. The incidence rates of
incident cancer-associated VTE, secondary non cancer-
associated VTE and idiopathic VTE, 1999–2009, appear to
be relatively constant [29]. The observed increase in
overall VTE and PE ± DVT incidence rates over the most
recent time period may, in part, reflect increased utilization
of objective imaging and improved image resolution, par-
ticularly computed tomography, pulmonary angiography,
and magnetic resonance imaging [18].
(3) What is the cumulative incidence of VTE recur-
rence, both overall and by leg DVT alone vs.
PE ± DVT?
VTE recurs frequently; about 30 % of patients develop
recurrence within the next 10 years (Fig. 4) [16, 31–41];
reported incidence rates of recurrent overall VTE,
PE ± DVT and DVT alone range from 19 to 39, 4-13, and
15 to 29 per 100,000 person-years, respectively [18]. The
hazard of recurrence varies with the time since the incident
event and is highest within the first 6–12 months but never
falls to zero. While secondary prophylaxis is effective in
preventing recurrence, the duration of acute treatment does
not affect the rate of recurrence after three months of
adequate anticoagulation has been completed [34, 35, 42–
46]. These data suggest that VTE is a chronic disease with
episodic recurrence [32, 33, 47, 48].
(4) What baseline and time-dependent characteristics
are independent predictors of VTE recurrence after
adjustment for primary treatment and secondary
prophylaxis? Within the major predictors of VTE
recurrence, can the individual patient be further
stratified into high and low risk? How well do
available VTE recurrence risk-prediction scores
operate in predicting recurrence?
Independent predictors of recurrence include increasing
patient age (per 10 years [32, 33, 35, 36, 49–54] and body
mass index (per 10 kg/m2) [32, 52, 54–57] male sex [32,
35, 51, 57–65], active cancer [12, 31, 32, 49, 66–71], and
neurologic disease with leg paresis [32]. Additional pre-
dictors of recurrence include idiopathic VTE [31, 36, 44,
59, 67, 68, 72–74], a lupus anticoagulant or antiphospho-
lipid antibody [43, 75], antithrombin, protein C or protein S
deficiency [76–78], hyperhomocysteinemia [79], a persis-
tently increased plasma D-dimer among patients with
idiopathic VTE [80–83], and possibly residual vein
thrombosis [84, 85]. Among active cancer patients, VTE
recurrence risk can be further stratified by cancer site
(pancreatic, brain, lung and ovarian cancer, myeloprolif-
erative or myelodysplastic disorders), stage IV cancer,
cancer stage progression and leg paresis [71].
Of equal importance, several risk factors present at the
time of the incident VTE event are associated with either a
reduced risk of recurrence or are not predictive of recur-
rence [31–33, 45, 59, 86]. For women, pregnancy or the
postpartum state [32, 39], oral contraceptive use [32],
hormone therapy [63, 87], and gynecologic surgery [32] are
associated with a reduced risk of recurrence. Recent sur-
gery and trauma/fracture either have no effect [32] or
predict a reduced risk of recurrence [31, 88]. Additional
characteristics having no significant effect on recurrence
risk include recent immobilization, tamoxifen therapy, and
Fig. 3 Secular trends in the incidence of venous thromboembolism,
deep vein thrombosis alone, and pulmonary embolism [18]
Fig. 4 Cumulative incidence of first venous thromboembolism
recurrence (continuous line), and the hazard of first recurrence per
1000 person-days (dotted line) [32]
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failed prophylaxis [32]. For these patients, and for patients
with isolated calf vein thrombosis, a shorter duration (i.e.,
6 weeks) of acute therapy likely is adequate [45, 67].
While data on the type of incident event type (DVT alone
vs. PE ± DVT) as a predictor of recurrence are conflicting
[32, 36, 37, 45, 50, 57, 89–92], patients with a recurrent
event are significantly more likely to have the same type of
VTE event as the incident event type [50].
Several VTE recurrence prediction scores have been
derived for stratifying recurrence risk among patients with
incident idiopathic or cancer-associated VTE. In the ‘‘Men
continue and HERDOO200 score, there were no predictors
of a reduced risk of recurrence among men with incident
idiopathic VTE. In contrast, women with idiopathic VTE
who had B1 of the following risk factors had a significantly
lower risk of VTE recurrence: (1) older age (C 65 years),
(2) obesity (BMI C 30 kg/m2), (3) an increased D-dimer
prior to stopping warfarin therapy and (4) signs of post
thrombotic syndrome [93]. In the Vienna prediction model,
male sex, incident VTE site (PE and proximal DVT vs.
isolated calf DVT) and increasing D-dimer level were
predictors of recurrence after idiopathic incident VTE [94].
In the DASH prediction score, a persistently increased
D-dimer after stopping anticoagulation therapy, age
\50 years, male sex and VTE unrelated to hormonal
therapy (in women) predicted an increased risk of recur-
rence after an ‘‘idiopathic’’ incident VTE [95]. Thus, the
only inconsistent risk factor in these models is the effect of
patient age, with older and younger age being associated
with a higher recurrence risk among women in the HER-
DOO2 model and among men and women in the DASH
model, respectively [93, 95], while patient age was not a
predictor of recurrence in the Vienna model [94]. Depend-
ing on the model, patients with a low score had 1.6–4.4 %
per year recurrence rates [96, 97]. Assuming these recur-
rence rates are acceptable, about 50 % of patients with
idiopathic incident VTE and a low prediction score could
avoid secondary prophylaxis [93–95]. Among active cancer
patients with VTE, patient sex, cancer site (lung, breast),
cancer stage and prior VTE were predictors of VTE recur-
rence while on anticoagulation therapy [70, 98].
(5) What are the attack rates (i.e. incident and recurrent
VTE) of VTE, both overall and by hospitalization-
related versus community-acquired VTE? What is
the total number of VTE events (incident and
recurrent) per year in the USA?
Estimated overall VTE attack rates range from 142 to
over 300 per 100,000 person-years; estimated attack rates
for PE ± DVT and DVT alone range from 51 to 75 and 91
to 255 per 100,000, respectively [18, 99]. Overall VTE
attack rates related to current or recent hospitalization are
much higher compared to rates among persons residing in
the community (330 vs. 8 per 100,000, respectively) [99].
There are few data on the total number of VTE events
(incident and recurrent) occurring in the USA per year, and
available estimates vary widely. Using age- and sex-
specific incidence rates for the five-year time period,
1991–95, projected to the 2000 United States white popu-
lation, at least 260,000 first-lifetime cases of VTE occur
among whites in the United States annually [13]. If inci-
dence rates among African-Americans are similar, then
27,000 additional incident cases occur among African-
Americans in the United States annually. In an incidence-
based modeling study that included both hospital- and
community-acquired, incident and recurrent VTE events,
an estimated 600,000 non-fatal VTE events (370,000 DVT
and 270,000 PE) occurred in the USA in 2005; of the total,
approximately two-thirds were related to current or recent
hospitalization [13]. Using 2007-2009 National Hospital
Discharge Survey discharge diagnosis codes, an estimated
average of about 548,000 hospitalizations with VTE
occurred each year among USA residents aged C18 years,
of which 349,000 were DVT and 278,000 were PE [100].
(6) What are the VTE-attributable costs?
In population-based studies, the adjusted mean predicted
costs were 2.5-fold higher for patients with VTE related to
current or recent hospitalization for acute medical illness
($62,838) compared to hospitalized controls matched on
active cancer status ($24,464; p\ 0.001) from the VTE
event date (or index date for controls) to 5 years post index;
cost differences between cases and controls were greatest
within the first 3 months (mean difference = $16,897)
[101]. Similarly, the adjusted mean predicted costs were
1.5-fold higher for patients with VTE related to current or
recent hospitalization for major surgery ($55,956) compared
to hospitalized controls matched to cases on type of surgery
and active cancer status ($32,718; p\ 0.001) from the VTE
event date (or index date for controls) to 5 years post index
[102]. Cost differences between cases and controls were
also greatest within the first 3 months after index (mean
difference = $12,381). Costs were significantly higher for
cases than controls (mean difference = $10,797) from
3 months to up to 5 years post-index and together accounted
for about half of the overall cost difference. Finally, the
adjusted mean predicted costs were over 2-fold higher for
patients with VTE related to active cancer ($52,422) com-
pared to active cancer controls matched on the duration of
active cancer ($23,951; p\ 0.001) from the VTE event date
(or index date for controls) to 5 years post index [103]. Cost
differences between cases and controls were greatest within
the first 3 months (mean difference = $16,488) but
remained significantly higher for up to 4 years after index.
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(7) What is the survival after VTE overall, and after leg
DVT alone vs. PE ± DVT. What are the indepen-
dent predictors of survival? What are the trends in
survival over time after PE ± DVT?
Overall, survival after VTE is worse than expected, and
survival after PE is much worse than after DVT alone
(Table 2) [37, 104–107]. The risk of early death among PE
patients is 18-fold higher compared with patients with
DVT alone [104]. Pulmonary embolism is an independent
predictor of reduced survival for up to 3 months after
onset. After 3 months, observed survival after PE is similar
to expected survival [15, 104, 105]. For almost one-quarter
of PE patients, the initial clinical presentation is sudden
death [104]. Independent predictors of reduced early sur-
vival after VTE include increasing age, male sex, lower
body mass index, confinement to a hospital or nursing
home at VTE onset, congestive heart failure, chronic lung
disease, serious neurologic disease, and active cancer [41,
104, 105, 108]. Additional clinical predictors of poor early
survival after PE include syncope and arterial hypotension
[108, 109]. Evidence of right heart failure based on clinical
examination, plasma markers (e.g. cardiac troponin T,
brain natriuretic peptide) or echocardiography predicts
poor survival among normotensive PE patients [108].
Survival over time may be improving for those PE patients
living sufficiently long to be diagnosed and treated [104,
106, 110, 111].
(8) What are the independent risk factors for VTE? How
well do incident VTE risk prediction scores operate
in predicting incident VTE for the individual?
Independent risk factors for VTE include increasing
patient age and body mass index, major surgery, hospital-
ization for acute medical illness, nursing home confine-
ment, trauma/fracture, active cancer with or without
concurrent chemotherapy, central vein catheterization or
transvenous pacemaker, prior superficial vein thrombosis,
varicose veins, neurologic disease with leg paresis, urinary
tract infection, an increased baseline plasma fibrin D-dimer
and family history of venous thromboembolism; patients
with chronic liver disease have a reduced risk (Table 3)
[112–118]. Compared to residents in the community, hos-
pitalized residents have over a 100-fold increased inci-
dence of VTE [119]. Hospitalization and nursing home
residence together account for almost 60 % of incident
VTE events occurring in the community [28, 120]. Of note,
hospitalization for medical illness and hospitalization for
surgery account for almost equal proportions of VTE (22
and 24 %, respectively). Nursing home residence inde-
pendently accounts for over one-tenth of all VTE disease in
the community [28, 120].
VTE risk among surgery patients can be further strati-
fied based on patient age, type of surgery, smoking and the
presence of active cancer [121–123]. The incidence of
postoperative VTE is increased for surgery patients
C65 years of age [124]. High VTE-risk surgical procedures
include neurosurgery, major orthopedic surgery of the leg,
thoracic, abdominal or pelvic surgery for cancer, renal
transplantation, and cardiovascular surgery [115, 124, 125].
Obesity [126–129], and poor American Society of Anes-
thesiology physical status [130] are risk factors for VTE
after total hip arthroplasty.
VTE risk among patients hospitalized for acute medical
illness may be further stratified based on increasing patient
age, obesity, previous VTE, thrombophilia, cancer, recent
trauma or surgery, tachycardia, acute myocardial infarction
or stroke, leg paresis, congestive heart failure, prolonged
immobilization (bed rest), acute infection or rheumatologic
disorder, hormone therapy, central venous catheter,
admission to an intensive or coronary care unit, white
blood cell count and platelet count [131–137].
While risk assessment models for predicting VTE
among hospitalized non-surgical patients have been
Table 2 Survival (%) after deep vein thrombosis vs. pulmonary
embolism [104]
Time Deep vein thrombosis alone Pulmonary embolism
0 days 97.0 76.5
7 days 96.2 71.1
14 days 95.7 68.7
30 days 94.5 66.8
90 days 91.9 62.8
1 year 85.4 57.4
2 years 81.4 53.6
5 years 72.6 47.4
8 years 65.2 41.5
Table 3 Independent risk factors for deep vein thrombosis or pul-
monary embolism [117]
Baseline characteristic Odds ratio 95 % CI
Body mass index (kg/m2) 1.08 1.05, 1.11
Major surgery 18.95 9.22, 38.97
Hospitalization for acute medical illness 5.07 3.12, 8.23
Nursing home confinement 4.63 2.77, 7.74
Trauma/fracture 4.56 2.46, 8.46
Active cancer 14.64 7.73, 27.73
Neurologic disease with leg paresis 6.10 1.97, 18.89
Pregnancy or postpartum 4.24 1.30, 13.84
Oral contraceptives 4.03 1.83, 8.89
Estrogen alone 1.81 1.06, 3.09
Non-contraceptive estrogen plus progestin 2.53 1.38, 4.63
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derived, the number, predictor types and strength of asso-
ciation with VTE are highly variable and lack generaliz-
ability and adequate validation [138, 139].
Active cancer accounts for almost 20 % of all incident
VTE occurring in the community [28, 120]. The risk
appears to be higher for patients with cancer of the brain,
pancreas, ovary, colon, stomach, lung, kidney and bone
[140, 141], and in patients with distant metastases [141].
Cancer patients receiving immunosuppressive or cytotoxic
chemotherapy are at even higher risk for VTE [112, 141],
including therapy with L-aspariginase [142, 143], thalido-
mide [144] or lenalidomide [145], or tamoxifen [146].
Routine screening for occult cancer is controversial and
likely not warranted. However, if clinical features suggest a
possible occult cancer (i.e. idiopathic VTE, especially
among patients with abdominal vein or bilateral leg vein
thrombosis [147] or in whom VTE recurs [148]) then the
only imaging study shown to be useful is a CT scan of the
abdomen and pelvis [148]. Among cancer patients, the risk
of chemotherapy-associated VTE is increased in patients
with pancreatic or gastric cancer, platelet count C350 9
109/L, hemoglobin \100 g/L or use of red cell growth
factors, leukocyte count C11 9 109/L, or body mass index
C35 kg/m2 [149]; biomarkers (plasma soluble P-selectin
and D-dimer) add further predictive value [150].
A central venous catheter or transvenous pacemaker
accounts for 9 % of all incident VTE occurring in the com-
munity [28]. Central venous access via femoral vein cathe-
ters is associated with a higher incidence of VTE compared
to subclavian vein catheterization [151]. Prior superficial
vein thrombosis is an independent risk factor for subsequent
DVT or PE remote from the episode of superficial throm-
bophlebitis [112, 152]. The risk ofDVT imparted by varicose
veins is uncertain and appears to vary by patient age [112,
153, 154]. Long haul ([4–6 h) air travel is associated with a
slightly increased risk for VTE (*1 per 4656 flights [155–
157]) that is preventable with elastic stockings [158]. HMG-
Coenzyme A reductase inhibitor (statin) therapy may pro-
vide a 20–50 % risk reduction for VTE [159–161]. Hyper-
triglyceridemia doubles the risk of VTE in postmenopausal
women [162]. However, the risk associated with
atherosclerosis, or other risk factors for atherosclerosis,
remains uncertain [118, 163–167]. Diabetes mellitus [117],
myocardial infarction [168], current or past tobacco smok-
ing, high-density lipoprotein cholesterol, lipoprotein (a),
chronic obstructive pulmonary disease, and renal failure are
not independent risk factors for VTE [112, 169, 170]. The
risk associated with congestive heart failure, independent of
hospitalization, is low [112, 121].
Among women, additional risk factors for VTE include
oral contraceptive use [117, 121, 171–173], hormone
therapy [117, 174, 175], pregnancy and the postpartum
period [121, 172, 176], and therapy with the selective
estrogen receptor modulator, raloxifene [177]. First and
third generation oral contraceptives convey higher risk than
second generation oral contraceptives [173]. Injectable de-
pot-medroxyprogesterone acetate for contraception is
associated with a three-fold increased risk for venous
thromboembolism, while a levonorgestrel intrauterine
device imparts no risk [178]. Hormone therapy is associ-
ated with a 2- to fourfold increased risk of VTE [117, 174],
but the risk may vary by type of estrogen [179] and there
may be no risk with transdermal estrogen therapy [180].
The overall incidence of pregnancy-associated VTE is
about 200 per 100,000 woman-years; compared to non-
pregnant women of childbearing age, the relative risk is
increased about fourfold [176, 181]. The risk during the
postpartum period is about fivefold higher than the risk
during pregnancy [176]. Prior superficial vein thrombosis
is an independent risk factor for VTE during pregnancy or
postpartum [182, 183].
Other conditions associated with VTE include autoim-
mune disorders [167], Behcet’s syndrome, celiac disease
[184], heparin-induced thrombocytopenia [185], homo-
cystinuria and hyperhomocysteinemia [186, 187], hyper-
thyroidism [188], immune thrombocytopenia (ITP) [189,
190], infection [114], inflammatory bowel disease [191],
intravascular coagulation and fibrinolysis/disseminated
intravascular coagulation (ICF/DIC), myeloproliferative
disorders (especially polycythemia rubra vera and essential
thrombocythemia) [192, 193], chronic kidney disease with
severely reduced glomerular filtration rate [194], nephrotic
syndrome [195], paroxysmal nocturnal hemoglobinuria
[196], rheumatoid arthritis [197, 198], obstructive sleep
apnea [199, 200], thromboangiitis obliterans (Buerger’s
disease), thrombotic thrombocytopenic purpura, sickle cell
disease [201], systemic lupus erythematosus, and granu-
lomatosis with polyangiitis (Wegener’s) [202].
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